BIOWA AND ONCOTHERAPY SCIENCE ANNOUNCE COLLABORATION

BioWa, Inc. and OncoTherapy Science, Inc. today announced that the two companies have entered into a collaboration to identify and develop cancer- focused monoclonal antibodies (Mabs). OncoTherapy Science will employ its technology for identification of the cancer antigens and generation of Mabs against those antigens, and BioWa will apply its POTELLIGENT(TM) technology to the Mabs for the enhancement of antibody-dependent cellular cytotoxicity (ADCC).

Yahoo News (http://biz.yahoo.com/prnews/051024/phm005.html?.v=30)